Feds Approve First-Ever Medicinal Marijuana Study
March 21st, 2014
Signaling a major shift in domestic drug policy, the U.S. federal government has signed off on a study of marijuana use for veterans with post-traumatic stress disorder (PTSD).
The study, to be conducted by Dr. Suzanne Sisley at the University of Arizona, will test the effects of five different THC potencies that will either be smoked or vaporized. 50 veterans will be studied.
Dr. Sisley calls the study’s federal approval “a historic shift in policy and medical marijuana drug development research.” Historically, all federally-approved studies on the effects of marijuana have been focused on the harmful aspects of the drug. Dr.Sisley clearly states that the focal point of her study is to identify potential benefits.
According to the National Center for PTSD, 11-20% of veterans that served in Iraq and Afghanistan suffer from PTSD. It has long been argued the use medicinal marijuana has the potential to suppress symptoms including flashbacks, insomnia and anxiety.
Regarding symptom suppression, Dr.Sisley told USA Today that there is a “mountain of anecdotal evidence” for using marijuana to treat PTSD.
Marijuana is particularly difficult to research, due to its classification as a Schedule I drug under the Substance Act — meaning it is considered as a drug with a high-risk of abuse with no medical applications.The American Medical Association has called for a change in marijuana’s classification, in order to make research more easily attainable, and eliminate barriers for doctors to prescribe medicinal marijuana to patients.
The study was already approved by the Food and Drug Administration, but without approval from the Department of Health and Human Services, researchers would not have been able to purchase marijuana from the National Institute on Drug Abuse (NIDA), the only government-sanctioned drug producer. The study now only seeks approval from the Drug Enforcement Administration, which is expected to be granted quickly.
The study is funded by the Multidisciplinary Association for Psychedelic Studies (MAPS), which supports the broad-based legalization and medical research of marijuana and other drugs. According to a statement, “MAPS has been working for over 22 years to start marijuana drug development research, and this is the first time we’ve been granted permission to purchase marijuana from NIDA.”
This study’s go-ahead is a very positive sign for cannabis traders, as it shows a newfound institutional openness to the idea of marijuana usage as a legitimate medical tool.
The study’s findings, meanwhile, have to potential to add a new element to the national debate on marijuana.
This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.
Follow Us on Social Media
About CFN Media Group
CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.
Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.